Short answer: what does the evidence say about CBD and fibromyalgia?
The best current evidence does not support ordinary CBD as a proven treatment for fibromyalgia. The most important new study is a 2026 randomised 1, double-blind, placebo-controlled trial of 200 people with fibromyalgia. Participants received 50mg plant-derived CBD or placebo daily for 24 weeks. Pain improved more in the placebo group than in the CBD group, and the authors concluded that the findings did not support CBD 50mg daily as an analgesic supplement for fibromyalgia. That result matters because older fibromyalgia content often grouped together CBD, THC-rich cannabis, mixed THC:CBD medicinal cannabis and observational studies as if they were interchangeable. They are not. A 2026 systematic review and meta-analysis reported pain reductions across cannabinoid studies, but rated the evidence low quality and highlighted substantial heterogeneity. Much of that literature involves THC-containing medicinal cannabis or observational data rather than over-the-counter CBD alone.
What is fibromyalgia?
Fibromyalgia is a long-term condition associated with widespread pain and increased sensitivity to pain. People may also experience fatigue, poor sleep, cognitive difficulties often described as “fibro fog”, headaches and other symptoms. The older version of this article correctly explained that fibromyalgia affects more than pain alone, but it overstated several proposed causes and mechanisms. Current NHS 2 guidance treats fibromyalgia as a complex condition requiring individualised management rather than one problem with one biological explanation. The NHS says treatment aims to ease symptoms and improve quality of life. The main approaches include:
- physical activity and exercise that can be maintained over time;
- talking therapies;
- medicines where appropriate;
- pacing, sleep and wider self-management support.
There is no single treatment that works for everyone. Read the NHS fibromyalgia treatment guidance
Why has CBD been investigated for fibromyalgia?
CBD, or cannabidiol, is one of the cannabinoids found in cannabis. Researchers have been interested in cannabinoids because pain processing, sleep, mood and the endocannabinoid system may all be relevant to chronic pain conditions. That gives researchers a reason to study CBD and other cannabinoids. It does not establish that a finished consumer CBD product works for fibromyalgia. This distinction is especially important because several different interventions appear in the literature:
| Research product | What it contains | Can it be treated as evidence for retail CBD? |
| Pure / plant-derived CBD | CBD without an intoxicating THC dose | Most directly relevant to a CBD-only question, but dose and formulation still matter |
| THC-rich cannabis | Predominantly THC with little CBD | No — different active cannabinoid profile |
| 1:1 THC:CBD medicinal cannabis | Both THC and CBD | No — efficacy or adverse effects cannot be attributed to CBD alone |
| Observational medical-cannabis use | Varied products and doses | Useful real-world context but much weaker for cause-and-effect conclusions |
| CBD cream or balm | Skin-applied cosmetic formulation | No direct fibromyalgia treatment conclusion unless that exact topical formulation has been studied |
The 2026 CBD-only trial: the most important update
A large recent trial gives us much better evidence than the older article had available. Rasmussen and colleagues randomised 200 people with fibromyalgia to 50mg plant-derived CBD or placebo daily for 24 weeks. The primary outcome was change in pain intensity. The CBD group improved by about 0.4 points, while the placebo group improved by about 1.1 points on the pain scale. The between-group result favoured placebo. Adverse events were generally mild and similarly distributed. The researchers concluded:
The findings did not support CBD 50mg daily as an analgesic supplement for patients with fibromyalgia.
That does not prove that every possible CBD dose or formulation can never be useful. It does, however, mean that a 2026 evidence-led article should not continue repeating older claims that CBD has been shown to relieve fibromyalgia pain. 2026 randomised CBD vs placebo fibromyalgia trial — PubMed
What does the 2026 cannabinoid meta-analysis show?
A 2026 systematic review and meta-analysis pooled 12 clinical studies involving 1,248 people with fibromyalgia. Across the combined cannabinoid literature, the authors found statistically significant reductions in pain and improvements in some secondary outcomes. But there are several reasons to interpret that cautiously:
- only two of the included studies were randomised controlled trials;
- most studies were observational;
- products and cannabinoid ratios varied substantially;
- many interventions contained THC as well as CBD;
- outcomes and study designs were highly heterogeneous;
- the authors rated the evidence low quality.
This is a good example of why “cannabinoids may help fibromyalgia” and “CBD treats fibromyalgia” are not equivalent statements. 2026 systematic review and meta-analysis — PubMed
What about THC:CBD medicinal cannabis?
A small randomised trial of a 1:1 THC:CBD cannabis oil reported preliminary signals for pain, sleep and fibromyalgia impact, but it involved only 24 adults and was designed primarily around feasibility and safety. Because the product contained THC and CBD together, the result cannot establish that CBD alone caused the observed changes. There is also an older small trial of THC-rich cannabis oil and an experimental inhaled-cannabis crossover study. These studies are relevant to the broader medical-cannabis question, but they are not evidence that an over-the-counter CBD food or cosmetic treats fibromyalgia. This separation is important both scientifically and legally.
What does NICE 3 4 say about CBD for chronic pain?
Fibromyalgia is included within NICE guidance on chronic primary pain. NICE’s cannabis-based medicinal products guideline says not to offer CBD to manage chronic pain in adults unless it is part of a clinical trial. The guidance separately recommends against several other cannabis-based medicines for chronic pain. NICE: cannabis-based medicinal products — chronic pain recommendations NICE’s chronic primary pain guidance also specifically identifies fibromyalgia as a type of chronic primary pain. NICE: chronic primary pain recommendations
CBD oil, gummies, cream and balm: are they interchangeable?
No.
CBD oils and gummies
These are ingestible CBD foods. They are used according to the finished product’s directions and current Food Standards Agency advice. A research dose used in a fibromyalgia clinical trial is not a serving recommendation for a retail CBD food. The FSA’s current precautionary advice for healthy adults is to limit CBD from food products to 10mg per day. That is consumer safety guidance, not a fibromyalgia treatment dose. Current UK CBD guidance
CBD cream and balm
Creams and balms are applied externally to the skin. There are small human studies of specific topical or transdermal CBD formulations in conditions such as hand osteoarthritis, but that does not establish topical CBD as a fibromyalgia treatment. Fibromyalgia is characterised by widespread symptoms, so evidence from one local topical formulation studied over one arthritic joint cannot simply be transferred to fibromyalgia. For the topical evidence itself, read our Topical CBD for Pain and Arthritis evidence guide. For the practical difference between formats, see What Are CBD Topicals? CBD Creams & Balms Explained.
Can CBD products claim to treat fibromyalgia in the UK?
An ordinary retail CBD food or cosmetic should not be marketed as treating fibromyalgia. The MHRA 5 states that products containing CBD used or marketed for a medical purpose are medicines. Medicinal claims therefore bring the product within the applicable medicines framework. For CBD foods, disease-treatment claims are also not permitted as ordinary food marketing. That means a retailer can:
- explain what CBD is;
- describe the product format and formulation;
- discuss published research accurately;
- link to independent clinical guidance;
- explain evidence limitations.
- claim its oil, gummy, cream or balm treats fibromyalgia;
- promise pain relief from fibromyalgia;
- imply it can replace prescribed treatment;
- use a study of THC-containing medicinal cannabis as proof that a CBD-only retail product works.
It should not:
What treatments are currently recommended?
The NHS says there is no single treatment for fibromyalgia and that management may involve a combination of approaches.
Exercise and physical activity
Regular activity can help some people reduce pain and improve quality of life. The appropriate level needs to be realistic and sustainable.
Talking therapies
Cognitive behavioural therapy and acceptance and commitment therapy may be used to help people manage the impact of long-term pain.
Medicines
Medication decisions depend on symptoms, other health conditions and individual response. This is something to discuss with a GP or specialist.
Sleep and self-management
Sleep problems, fatigue and pacing are often important parts of the condition, but persistent symptoms should be managed with appropriate clinical advice rather than a retail supplement promise. NHS: Fibromyalgia — treatment
How to read CBD-and-fibromyalgia claims online
Before accepting a claim, ask:
- Was the study actually in people with fibromyalgia?
- Was it randomised and placebo-controlled?
- Was the intervention CBD alone, THC, or a THC:CBD combination?
- Was it an oral product, inhaled cannabis, or a topical?
- How many participants were included?
- How long did the study last?
- Was the result statistically and clinically meaningful?
- Is a retailer applying research on one formulation to a completely different consumer product?
- Are negative trials — including the 2026 CBD-only trial — being omitted?
If you are considering CBD alongside fibromyalgia care
If you have fibromyalgia and are considering an ingestible CBD product, speak with a GP or pharmacist if you take medication or have other health conditions. Do not stop prescribed treatment because of an article or product claim. If you are comparing an external-use cream for a normal massage/body-care routine, the High-Strength CBD Cream product page contains its exact 1000mg specification, ingredients and directions. That product information should remain separate from the fibromyalgia evidence above.
The bottom line
The evidence around cannabinoids and fibromyalgia is more developed than it was when the original version of this article was written — but it has also become more complicated. A 2026 meta-analysis reports possible benefits across mixed cannabinoid studies, but the evidence quality is low and the interventions vary widely. More importantly for a page specifically about CBD, the 2026 randomised CBD-only trial involving 200 people did not support CBD 50mg daily as an analgesic supplement for fibromyalgia. So the responsible conclusion is: CBD is being studied, but it is not a proven fibromyalgia treatment. Evidence involving THC-containing medicinal cannabis should not be used as proof that an over-the-counter CBD oil, gummy, cream or balm works for fibromyalgia.
Frequently Asked Questions
Can CBD products claim to treat fibromyalgia?
No. Retail CBD products should not be marketed as treating, preventing or curing fibromyalgia. The condition needs appropriate clinical assessment and care.
What does research say about CBD and fibromyalgia?
Research is mixed and includes different cannabinoids, routes and study designs. A recent CBD-only randomised trial did not show better pain outcomes than placebo, so broad treatment claims are not justified.
Are CBD oil and topical CBD the same evidence?
No. Oral products, topical cosmetics, transdermal gels and medicinal cannabis formulations use different routes and cannabinoid profiles. Findings from one cannot automatically be applied to another.
Can a CBD cream replace fibromyalgia treatment?
No. A cosmetic CBD cream is not a licensed fibromyalgia treatment and should not replace medical advice, prescribed treatment, pacing or other evidence-based care.
Where can I compare topical formats?
Use the CBD topicals guide to compare creams and balms by texture and formulation. The dedicated High-Strength CBD Cream page contains the current commercial specification and directions.
References and further reading
- Rasmussen et al. — Cannabidiol versus placebo in patients with fibromyalgia, 2026
- Lam et al. — Analgesic Effect of Cannabinoids for Fibromyalgia: systematic review and meta-analysis, 2026
- Randomised pilot of 1:1 THC:CBD medicinal cannabis oil
- NICE — Cannabis-based medicinal products
- NICE — Chronic primary pain
- NHS — Fibromyalgia treatment
- GOV.UK — Cannabidiol guidance
- MHRA — Products containing cannabidiol
Production image briefs
- Randomised pilot of 1:1 THC:CBD medicinal cannabis oil. https://pubmed.ncbi.nlm.nih.gov/42142029/
- NHS — Fibromyalgia treatment. https://www.nhs.uk/conditions/fibromyalgia/treatment/
- NICE — Chronic primary pain. https://www.nice.org.uk/guidance/ng193/chapter/recommendations
- NICE — Cannabis-based medicinal products. https://www.nice.org.uk/guidance/NG144/chapter/recommendations
- MHRA — Products containing cannabidiol. https://www.gov.uk/government/publications/mhra-statement-on-products-containing-cannabidiol-cbd/mhra-statement-on-products-containing-cannabidiol-cbd